[Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
Antineoplastic drugs have been shown to exert direct effects on the gut and induce the release of serotonin from the enterochromaffin cells of small intestinal mucosa. It is thought that released serotonin stimulates vagal afferent fibers through 5-HT3 receptors located in the vagal afferent terminals in the gastrointestinal tract and initiates sensory signals to the area postrema and the emetic center, thereby initiating nausea and vomiting. A 5-HT3 antagonist competitively inhibits serotonin at its specific binding sites, 5-HT3 receptors, and thereby elicits an antiemetic effect. Therefore 5-HT3 receptor occupancy of serotonin may be an appropriate indicator of the antiemetic activity of 5-HT3 antagonists. We analyzed 5-HT3 receptor occupancy of serotonin by integrating pharmacokinetic and receptor-binding kinetic parameters based on the receptor occupancy theory to compare the strength of the antiemetic effects of three dosage regimens of azasetron hydrochloride. The inhibitory effects on the binding of serotonin to 5-HT3 receptor of regimen 2 (an intravenous bolus injection of 5 mg of azasetron hydrochloride before and 8 h after chemotherapy) and regimen 3 (an intravenous bolus injection of 2.5 mg followed by 7.5 mg continuous intravenous infusion for 24 h) were longer-lasting than those of regimen 1 (an intravenous bolus injection of 10 mg before the start of chemotherapy). Furthermore, a positive relationship was found between the time of inhibitory effects on the binding of serotonin to 5-HT3 receptor and antiemetic effects of azasetron hydrochloride. From these results, dosage regimens 2 and 3 were considered to be more effective in the long term than regimen 1 in prophylaxis of nausea and vomiting induced by cisplatin.
Yamada
Yasuhiko
Y
Department of Clinical Evaluation of Drug Efficacy, Tokyo University of Pharmacy and Life Science, Horinouchi, Hachioji City, Japan. yamada@ps.toyaku.ac.jp
Fujita
Mina
M
Okuyama
Kiyoshi
K
Takayanagi
Risa
R
Ozeki
Takeshi
T
Yokoyama
Haruko
H
Iga
Tatsuji
T
D000932:Antiemetics / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000009:adverse effects; D001667:Binding, Competitive; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D002945:Cisplatin / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D007275:Injections, Intravenous; D008954:Models, Biological; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D010078:Oxazines / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D010078:Oxazines; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; D012701:Serotonin; C070671:azasetron; D002945:Cisplatin